Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Ultra-low-dose Total-skin Electron Beam Radiation Therapy with Brentuximab vedotin for the Treatment of Stage I-IV Mycosis Fungoides

Trial Status: active

This phase II trial tests whether ultra-low-dose total-skin electron beam therapy with brentuximab vedotin work in treating patients with mycosis fungoides. Total skin electron beam radiation is a type of radiation therapy that targets the entire skin. It uses high energy rays to kill cancer cells and shrink tumors. Brentuximab vedotin is a monoclonal antibody, brentuximab, linked to a toxic agent called vedotin. Brentuximab attaches to CD30 positive cancer cells in a targeted way and delivers vedotin to kill them. Giving total skin electron beam radiation in combination with brentuximab vedotin may be more effective in treating mycosis fungoides.